ArticleAmerican journal of translational research2026
Domperidone plus pinaverium bromide and itopride for functional dyspepsia in the elderly: efficacy, symptom improvement, and gastric function panel.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFocusing on functional dyspepsia (FD) in the elderly, this study analyzes how the triple therapy consisting of domperidone (DPD), pinaverium bromide (PB), and itopride (ITP) impacts curative efficacy, symptom amelioration, and the gastric function (GF) panel.
methodsA total of 96 elderly FD adults were selected and allocated to a control group treated with PB+ITP or a research group which additionally received DPD in addition to PB+ITP. Outcome measures included curative efficacy, symptom amelioration, gastric accommodation, electrogastrographic parameters (dominant frequency, dominant power), brain-gut axis (BGA)-related factors (vasoactive intestinal peptide [VIP], somatostatin [SS], calcitonin gene-related peptide [CGRP], serum neuropeptide S receptor 1 [NPSR1]), GF panel (pepsinogen [PG] I, PG II, gastrin [G]-17), other serum indices (motilin [MTL], 5-hydroxytryptamine [5-HT], nitric oxide [NO]), and adverse events.
resultsAccording to statistics, the total effective rate was higher in the research group compared to controls, and the time to symptom improvement was shorter (P<0.05); The post-treatment gastric accommodation, dominant frequency, dominant power, NPSR1, GF panel, and MTL were higher in the research group, while VIP, SS, CGRP, 5-HT, and NO were lower (P<0.05); the total incidence of adverse reactions was equivalent across groups.
conclusionThe triple therapy (DPD+PB+ITP) demonstrates high therapeutic efficacy on elderly FD patients, helps improve symptoms, and actively up-regulates GF panel levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.